CN1298317C - Tamsulosin tablets - Google Patents

Tamsulosin tablets Download PDF

Info

Publication number
CN1298317C
CN1298317C CNB028217357A CN02821735A CN1298317C CN 1298317 C CN1298317 C CN 1298317C CN B028217357 A CNB028217357 A CN B028217357A CN 02821735 A CN02821735 A CN 02821735A CN 1298317 C CN1298317 C CN 1298317C
Authority
CN
China
Prior art keywords
tablet
tamsulosin
active substance
medicinal tablet
admixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028217357A
Other languages
Chinese (zh)
Other versions
CN1652760A (en
Inventor
J·J·普拉图夫
F·范达兰
J·M·莱蒙斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthon BV
Original Assignee
Synthon BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23292437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1298317(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synthon BV filed Critical Synthon BV
Publication of CN1652760A publication Critical patent/CN1652760A/en
Application granted granted Critical
Publication of CN1298317C publication Critical patent/CN1298317C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is directed towards pharmaceutical tablets comprising low amounts of tamsulosim. These tablets are obtainable by a manufacturing process without the use of a liquid. The invention further relates to the manufacturing process and the therapeutic use of these compounds for the treatment of bening prostatic hyperplasia.

Description

The tamsulosin tablet
Background of invention
The present invention relates to comprise the medicinal tablet of tamsulosin (tamsulosin), by the unit dosage forms of their preparations with prepare the method for this medicinal tablet.
Tamsulosin is 5-[2-[[2-(2-ethoxy phenoxy) ethyl of following formula (1)] amino] propyl group]-common name of 2-methoxyl group-benzsulfamide.
Figure C0282173500051
It is disclosed among EP 34432 and the US 4731478 as having the active pharmaceutically active substance of alpha-adrenergic blockade, is used for the treatment of cardiac insufficiency and benign prostatic hyperplasia.
The enantiomer of hydrochloride form (R)-tamsulosin goes on the market in each country that comprises the U.S., is used for the treatment of the benign prostatic hyperplasia symptom of (also claiming BPH), for example the numerous problem of urine amount and frequent micturition.The medicine of above-mentioned approved is the oral capsule dosage form, only comprises the tamsulosin hydrochloride of 0.4mg.This capsule provides the tamsulosin controlled release, and is a kind of dosage form once a day, though can take two capsules if necessary, promptly takes 0.8mg once a day.
US 4,772, and 475 (EP 194838, and EP 533297) disclose the pharmaceutical dosage forms for controlled release that comprises many granules unit, and this granule unit comprises tamsulosin, microcrystalline Cellulose and release control agent.Described granule discharges tamsulosin gradually from particle matrix.Think now that at US 4,772 invention disclosed thought and compositions have covered the capsule product of commercial listing in 475.
The method of the described granule unit of disclosed production comprises the granulating mixture that tamsulosin, unit is formed inert substance such as microcrystalline Cellulose and release control agent, and described release control agent comprises aqueous emulsion, suspension or gel or the solution of said macromolecular substances in water-containing organic solvent of water and/or water-insoluble macromolecular substances.This macromolecular substances preferentially is selected from brand name Eudragit The acrylate polymer series of commercial distribution.Described release control agent also plays binding agent basically in pelletization.Resulting granules can be used for preparing final dosage form, capsule and tablet.
US 4,772, and 475 embodiment 1 has explained said method.After fully mixing 5g tamsulosin hydrochloride and 470g microcrystalline Cellulose, to the mixture that wherein adds 83.3g (25g is as solid constituent) Eudragit L 30 D-55 and 500g water, then with super mixer with the gained granulating mixture.The gained granule is for having 0.1 to 1.5mm, mainly the spheroid of 0.2 to 1.0mm particle size.In view of mixed phase a spot of active substance for figuration dosage, in forming granule, obviously need using liquid (being water in this example), this is not wondrous.Certainly, must remove described water after the granulation, this makes the very time-consuming and power consumption of this method.Remove the difficulty especially of anhydrating from the inside of solid particle.In addition, can cause the formation of unwanted by-product for the temperature of suitably dry necessary raising.Described impurity also can form by hydrolysis or by the effect that is dissolved in the oxygen in the water.If use the solvent outside dewatering in pelletization, situation is also like this substantially.
US 4,772, and 475 have also stated a kind of formation of tablet, this tablet conduct and capsular comparative product.Described tablet comprises tamsulosin hydrochloride, lactose, starch/corn starch and gelatinized corn starch.The existence of gelatinized corn starch shows that described tablet also is by aqueous methods, promptly by being used for described particulate same procedure preparation, increases the probability of described same disadvantages.
Can be in mixing water or liquid prepares the tamsulosin medicinal tablet or dosage form will be useful not.Though dry method is generally known, comprise direct compression and dry granulation technology, think that the amount that these class methods are not suitable for active substance is less than 2% dosage form by weight, when the amount of used active substance was less than 1%, these class methods were unacceptable.
Summary of the invention
Have now found that, do not need water or solvent just can prepare tablet with containing of good content uniformity of a small amount of tamsulosin active substance.Therefore, one aspect of the present invention relates to a kind of medicinal tablet of dry process, and this tablet comprises 0.1 to 1.5% tamsulosin active substance and at least a pharmaceutically acceptable excipient.Astoundingly, tamsulosin is a kind of easy dispersive active substance, although therefore use on a small quantity, it also is to be fit to dry method.Because this feature, can prepare a collection of medicinal tablet, what this batch tablet comprised a large amount of dry processes contains the tamsulosin active substance between 0.1 and 1.5% and the sheet of at least a pharmaceutically acceptable excipient, wherein the difference of the tamsulosin active matter quality between the sheet is not more than 10%, preferably be not more than 5%, more preferably no more than 2.5%.
Another aspect of the present invention relates to the unit dosage forms that is used for the treatment of or improves the benign prostatic hyperplasia situation, and it comprises the tablet of one or more pieces above-mentioned dry processes of effective dose.Advantageously, described tablet composition basically bioequivalence in the listing capsule form.In one embodiment, take, several pieces or number small pieces are placed capsule for easier.
Another aspect of the present invention relates to the method for preparing the tamsulosin tablet, and it is not included in and forms tablet under the situation by liquid, and wherein said tablet contains 0.1 to 1.5% tamsulosin active substance and at least a pharmaceutically acceptable excipient.Preferably, this method comprises tamsulosin active substance and a kind of pharmaceutically acceptable excipient fusion and forms first admixture; Additionally above-mentioned first admixture and one or more other excipient are formed the precommpression admixture with a step or multistep fusion; And in flakes with above-mentioned precommpression admixture compacting.In certain embodiments, grinding after the fusion first or after optional compaction step as dry granulation technology part.
Detailed Description Of The Invention
The present invention relates to the method for medicinal tablet and this tablet of preparation of comprising of dry process of a small amount of tamsulosin active substance.As used herein " tamsulosin active substance " is meant any material that contains tamsulosin part that shows pharmaceutically active, specifically comprises two or more mixture or the compositions in tamsulosin free alkali, its pharmaceutically acceptable salt, particularly its pharmaceutically acceptable acid-addition salts and any this class tamsulosin material.The example of the useful pharmaceutically acceptable salt of tamsulosin comprises tamsulosin hydrochloride, tamsulosin bromide, tamsulosin mesylate, tamsulosin toluene fulfonate, tamsulosin benzene sulfonate, tamsulosin acetate, tamsulosin maleate, tamsulosin tartrate and tamsulosin citrate.Usually use described hydrochlorate.Be present in tamsulosin (the R)-enantiomer of tamsulosin normally in the tamsulosin active substance, still (S)-enantiomer and comprising in the mixture or above-mentioned implication that racemic mixture is also included within the tamsulosin active substance of above-mentioned two kinds of enantiomer of equimolar various ratios.
Usually with powder, promptly the form of fine particle is used the tamsulosin active substance.Described particle can have diversified particle size distribution, but at least 90% particle size of preferred described particle is 100 microns or littler, and more preferably 50 microns or littler, also more preferably 20 microns or littler, most preferably 10 microns or littler.Usually littler particle size helps to form uniform admixture, and the target that helps to reach content uniformity.If by being fit to means such as scanning electron microscopy inspection, the particle of the tamsulosin active substance in the dry process tablet is normally identifiable.Therefore above-mentioned size distribution is applicable to the tamsulosin active substance in all stages of film-making process, comprises as free powder, as with the admixture of one or more excipient and in tablet itself.
The amount that is present in the tamsulosin active substance in the described tablet is lower, and promptly 0.1 to 1.5%.All percentage ratios are meant the percetage by weight based on described tablet total weight as used herein, and do not consider any coating above it, except as otherwise noted.The amount of tamsulosin active substance in 0.1 to 1.2% scope, more typically is in 0.2 to 1.0% scope typically, preferably in 0.2 to 0.8% scope, and is in many embodiments in 0.3 to 0.6% scope.With absolute magnitude, the amount of tamsulosin active substance typically in 0.3 to 1.2mg scope, and preferably in 0.3 to 0.8mg scope, is shown with the scale of free alkali normally in 0.1 to 1.2mg scope.For example, the 0.4mg tamsulosin hydrochloride is the preferred amounts of tamsulosin active substance, and it is equivalent to 0.367mg tamsulosin free alkali.A preferred embodiment of the present invention contains 0.4mg+/-0.04 tamsulosin hydrochloride or its multiple, i.e. 0.8mg.
Tablet of the present invention also comprises at least a pharmaceutically acceptable excipient." excipient " meaning is meant any pharmaceutically acceptable non-activity composition of compositions as used herein.As known in the art, excipient comprises diluent, binding agent, lubricant, disintegrating agent, release aromatics modifier, coloring agent, antiseptic, pH regulator agent etc.Based on the easy degree/cost of the needed physics aspect of final form, its picked-up back active substance needed rate of release and production from compositions, select described excipient.Usually, tablet of the present invention contains at least a in pharmaceutically acceptable polymer, carbohydrate or the compressible diluent.These kinds are not to repel mutually, and in fact some chemical compounds will have at least two kinds qualification of mentioned kind; Be microcrystalline Cellulose be a kind of polymer be again a kind of compressible diluent.Described polymer comprises the polymeric material of wide range, comprises that substrate forms polymer, corrodible polymer, water-soluble polymer, insoluble polymer, water-swellable polymer, pH sensitive polymer and pH insensitivity polymer and other.The instantiation of the polymer that is fit to comprises cellulose family such as microcrystalline Cellulose, cellulose acetate, ethyl cellulose, hydroxypropyl cellulose and hydroxypropyl emthylcellulose (HPMC); Esters of acrylic acid, methyl acrylic ester and have the monomeric copolymer of different copolymer; And polyvinylpyrrolidone class.Carbohydrate comprises lactose, mannitol, maltodextrin, cyclodextrin, dextrates and dextrin.Compressible diluent comprises any pharmaceutically acceptable diluent, particularly calcium phosphate such as dicalcium phosphate dihydrate and the anhydrate form that is fit to direct compression.
Usually prepare described tablet with diluent or carrier.Microcrystalline Cellulose is the suitable inert carrier that tamsulosin is mixed with tablet by the inventive method.A suitable brand of microcrystalline Cellulose is Avicel TMPH102.Alternately, Lactis Anhydrous, starch, calcium phosphate dibasic anhydrous, mannitol or maltodextrin can be used as suitable carrier.Can also form described inert carrier by two or more mixture of ingredients.A mixture that preferred embodiment is Lactis Anhydrous and calcium hydrogen phosphate of combination.
Except above-mentioned diluent/carrier, described tablet also optionally contains release control agent or replaces above-mentioned diluent/carrier with release control agent.The suitable release control agent that is used for tablet composition of the present invention can comprise that common approval is used for any suitable solid acrylic ester/methacrylate polymers/copolymer of medicament purpose, for example dissimilar Eudragit or Carbopol.Alternately, it can comprise cellulose derivative such as different brackets ethyl cellulose, hydroxypropyl cellulose or, preferably, HPMC (Methocel TM) or polyvinylpyrrolidone (Kollidon TM).Get rid of especially water and aqueous solution are used as release control agent.With regard to the amount of release control agent, be not particularly limited.Yet, it should be processed into tablet form with tamsulosin composition and described inert carrier by direct compression or dry granulation, thereby the tablet with required physical parameter is provided.The above-mentioned release control agent in the tablet composition and the character and the grade of inert carrier, and the mutual ratio of two kinds of batchings may have decisive influence to final rate of release.For example, replace the water-insoluble microcrystalline Cellulose, when it is contacted with body fluid, can cause gel formation faster, so it provides the release characteristics that more postpones with the water solublity lactose.On the other hand, the HPMC of various viscosity grades allows closely similar dissolution characteristic.Concerning water solublity or very the medicine of low concentration, the main influence of diffusion total dissolution and proportional with the polymer concentration of any (relative high) viscosity.
Before the material that tamsulosin salt is used as in direct compression or the dry granulation process in blocks, also can change its release characteristic by its hydrophobic treatment that is fit to, for example by its microcyst is gone in the wax shell.Hydrogenated vegetable oil such as castor oil hydrogenated are the examples that is fit to wax.Can prepare the tamsulosin microparticle (diameter is less than 0.1mm) of above-mentioned such production by any dry method.In one embodiment, the tablet of being prepared can comprise disintegrating agent, and this disintegrating agent allows described tablet to decompose in gastric environment, disengages the microparticle that has the microencapsulation tamsulosin in a large number.Above-mentioned then microparticle discharges tamsulosin with desired rate.
In another embodiment, two class release control agents can be combined the time dependence and the control of pH dependency of inducing tamsulosin to discharge.Do not rely on environment pH and discharge the application of the controlling agent of above-mentioned active substance, dosage inclines to can to prevent described tablet surface to contact afterwards with body fluid, and the controlling agent of the above-mentioned active substance of pH dependent release then allows to concentrate the major part of described active component to be released into the gastrointestinal desired area.With pH irrespectively an example of the polymer of h substance be Eudragit RS PO, Methocel K4 MP, Carbopol 971P NF or KollidonSR, and Eudragit L 100-55 is the polymer of the described active substance of pH dependent release.Two kinds of Eudragit types all are powder and needn't before mixing described tablet they be suspended in the liquid excipient.
Because of preparing tablet of the present invention by anhydrous flaking method, therefore should between above-mentioned basic inert excipient, make one's options, only select this class to have the batching of the suitable character that is used for the dry compression method, get rid of other batching.For example, the inert carrier that is used for compressing method should have good bond property,, opposite with the tamsulosin compositions of prior art, described release control agent does not need to show the character of binding agent, although do not get rid of this character.
Two kinds of common vehicle compositions are useful in tablet of the present invention.A kind of microcrystalline Cellulose and release aromatics modifier such as one or more acrylate polymers that comprises as matrix polymer; Be Eudragits TMAbove-mentioned composition preferably also comprises lubricant such as magnesium stearate.Another kind of common compositions comprises calcium phosphate such as anhydrous dicalcium phosphate and HPMC.This embodiment preferably additionally contains carbohydrate such as lactose anhydride.Also preferably comprise lubricant such as magnesium stearate.Relative amount is not particularly limited, but preferred, and these two or three excipient (cellulose, calcium phosphate and lactose) alternatively account for the major part of described excipient, as 75% or more.Specifically, preferred following amount: 25 to 40%HPMC, 25～40% calcium phosphate and 25 to 40% lactose.More preferably, described tablet contains and has an appointment 30 to 40%HPMC.Basically the HPMC of equivalent, calcium phosphate and lactose, promptly each is about 30 to 35% concerning total 90 to 99.9%, is particularly preferred embodiment.Also can there be the other excipient that comprises lubricant etc.From the angle of performance repeatability, this second kind of common compositions is preferred.
Can be for example with casing or be painted simply or the described tablet of stability reasons coating.
In general, described tablet can guarantee instant-free, promptly in 1-30 minute, guarantees slow release or slow release after picked-up, promptly discharges in several hrs, or guarantees to postpone to discharge, and discharges after promptly certain incubation period.Required rate of release can be according to practical application, therapeutic purposes and therapeutic dose or the administration frequency and different of expection.Yet preferably, tablet of the present invention be basically bioequivalence in the listing capsule product slow releasing tablet.From this respect, tablet of the present invention is the tablet of " once a day " preferably, and the meaning is meant that the routine or the typical doses scheme that are used for the patient will be to take a slice once a day.Further offer some clarification on preferred rate of release hereinafter.
The tablet that makes by the inventive method is preferably the monoblock type tablet, and promptly not disintegrate forms many littler particles after this tablet picked-up, and active component finally discharges from these particles.But described product weathers in vivo at the active substance deenergized period.Therefore, in monoblock type tablet embodiment, there is not a kind of disintegrating agent that plays a part in the excipient that in production method of the present invention, uses.More preferably described tablet is the monoblock type slow releasing tablet.
Therefore, the present invention provides a kind of new tamsulosin oral Pharmaceutical dosage forms to its patient of needs.Specifically, it provides a kind of tablet, particularly slow releasing tablet, and wherein tamsulosin and/or its salt (particularly hydrochlorate) are evenly dispersed in the tablet matrix, and it is prepared by anhydrous process.
Advantageously, tablet of the present invention should show following preferred rate of release in the external dissolution test that carries out:
-under 100rpm by changeing the basket method, described dosage form during stripping, has obtained following release characteristics in the pH6.8 phosphate buffer:
In the 15-35% 30 minutes
In the 40-75% 2 hours
In the 70-100% 5 hours
Under 50rpm, will obtain identical preferred release characteristics with alternative oar method.
Be therapeutic purposes, the bio-absorbable of tamsulosin in body fluid should preferably be carried out in small intestinal.Therefore, can also be with the anti-stomach coatings protect tablet of the present invention that is fit to, this coating postpones the beginning that active component discharges from tablet matrix during described tablet passing through under one's belt.The example that is used for the material that this class of anti-stomach coating is fit to is CAP (CAP) (Aquacoat TM), the polyvinyl acetate phthalate (Suretetic of processing altogether TM), acetic acid 1,2,4-benzenetricarboxylic acid cellulose (CAT), Eudragit base polymer (copolymer of methacrylic acid copolymer, methacrylic acid copolymer latex, methacrylic acid and (methyl) acrylate, acetic acid succinic acid hydroxypropyl emthylcellulose (HPMCAS), carboxymethylethylcellulose (CMEC), polyvinyl acetate phthalate (PVAP)).
Can also test the releasing properties of described coating with the dissolution test of the coated tablet of producing.The preferred property of coated tablet is, for example:
-change the basket method and under 100rpm, in the dissolution test of described dosage form in the SGF buffer, discharged 10% tamsulosin at most with Ph.Eur..
-in the buffer of pH6.8, described coated tablet should be followed dissolution characteristic same as described above.
The unit dosage forms that tablet of the present invention could directly be used as or not have coating uses, maybe can with two or more the multi-disc combination for example in capsule, form unit dose.Described unit dosage forms contains the tamsulosin of effective dose for treatment or improvement and BPH, hypertension or congestive heart failure diseases associated, symptom and/or situation, and dosage is usually from 0.01 to 10.0mg, and preferred 0.1 to 1mg, by described free alkali.Preferably comprise 0.2,0.4 or the unit dose of the tamsulosin hydrochloride of 0.8mg itself.Take unit dose 1 to 3 time every day routinely, preferred once a day as mentioned above.Under capsular situation, the sheet of sufficient amount is provided or is small pieces more rightly based on the concentration of tamsulosin active substance wherein, so that effective amount is provided.
Consider the therapeutic dose that tamsulosin is habitual, preferably 10 and 300mg between the tablet of gross mass.Because the therapeutic dose of tamsulosin is lower, it is low as much as possible that the gross weight of described tablet advantageously keeps.The tablet that gross weight is low has increased the relative amount of tamsulosin in the tablet, has therefore improved content uniformity.And small pieces will have the gastrointestinal transit speed similar to granulated product; Therefore, the result who obtains from external dissolution test can predict and the actual bioequivalence of the granulated product of going on the market better.From this respect, the preferred sheet in the present invention heavily is to 250mg, although it is not limited to this scope from 25.Most preferred heavily is about 100mg.
Therefore, tablet of the present invention can be small pieces, so as to-no matter when the average diameter of rounded production-sheet is from about 1.5 to about 2.5mm, perhaps also can be used as ordinary tablet production they, the average diameter of sheet is between 2.5 to 15mm.Except circle, the tamsulosin compositions can be compressed into ellipse, circle biconvex, pentagon circumscribed circle or other sheet shape that is fit to.
The tablet of the present invention that comprises unit dose amount tamsulosin can be suitable packing unit and send to pass and be used for instant application, and this packing unit advantageously comprises 5 to 100.This packing can comprise and advantageously comprises 10,14,20,28 or 30 bubble-cap, or contain the plastics or the glass container/bottle of equal number sheet.In producing above-mentioned packing unit, can use any suitable pharmaceutically acceptable packaging material.
If with tamsulosin active substance and described excipient composition or be dispersed in the described excipient, be the object of the invention so under without the situation of liquid, medicinal tablet is " dry process ".Usually, under scanning electron microscope, check, the structure of the tablet of dry process is different from the tablet of the tablet, particularly wet granulation of comparable wet method preparation, therefore just can differentiate it like this under the situation that need not actually see production method.Specifically, liquid, normally water can cause active substance or excipient or their the two variations at aspects such as granular size, agglomeration, granule formation.Usually in the tablet of dry process, tamsulosin active substance and at least a excipient will keep their original form and/or for more tiny.
Prepare tablet of the present invention by a kind of like this method, this method is assisted equably the tamsulosin active substance is blended in the excipient without liquid.These class methods comprise the direct compression and the dry granulation of the mixture of powders of tamsulosin active substance and suitable inert excipient.Therefore, the invention provides and a kind ofly be tablet form, comprise the preparation of direct compression and tamsulosin dried mixed with excipients and be tablet form, comprise preparation dry granulation and compacting and tamsulosin dried mixed with excipients.
Following technology will help the homogeneity of described powder admixture:
-progressively mix
In initial blend step, effectively with a part of fusion of described tamsulosin active component and inert carrier, in second blend step, can be with the pre-admixture of this solid and remaining solid excipient fusion.
-grind altogether
Described active substance is ground with at least a portion of carrier or release control agent.With the homogeneous mixture that grinds with remaining batch mixes and stand compacting in flakes.This technology more specific forms is a micronization.
-on solid carrier, absorb
Before process for preparation, solution or the suspension of tamsulosin active component in being fit to liquid-carrier contacted with solid inert carrier and evaporate described liquid (for example passing through spray drying) immediately; As a result, gain freedom mobile powder or microparticle, they are as the initial tamsulosin active substance composition of dry mixed step.
In a kind of preferable methods, with tamsulosin active substance and pharmaceutically acceptable excipient fusion and form first admixture.Then this first admixture is carried out other fusion step, in this step, in above-mentioned admixture, add one or more other excipient, form the precommpression admixture.Then this precommpression admixture compression is formed sheet.
Processing in addition can be carried out or combine with them carrying out between these steps.For example, grinding is preferably being carried out after forming first admixture and before adding other excipient.In the course of processing, all can grind any time, be included in before the first fusion step, after the first fusion step, fusion step (or a few step) in addition before or during and in fusion step (or a few step) in addition afterwards.Described fusion itself can be progressively, promptly to wherein add, the part of fusion excipient, add more excipient, further fusion etc.
The dry granulation that is also referred to as compaction can also be combined application with this processing.Specifically, first admixture or any follow-up admixture that contains other excipient are compressed, grind then and form second admixture.According to amount or kind can in this second admixture, add other excipient and fusion they.Alternately, above-mentioned second admixture can be to be ready for use on compacting final precommpression admixture in blocks.
Be described in more detail below according to direct compression process of the present invention.By be fit to size as the sieve of 0.5mm with as described in excipient sieve, and in blender that is fit to such as free-falling blender, above-mentioned mixed with excipients that will be except lubricant is to provide a kind of uniform mixture.At last, can add described lubricant and mix said mixture once more.The precommpression mixture is changed in the charging chamber of sheeting equipment over to compacting then in flakes.All the operation time spent is no more than 1 hour.
Be described in more detail below according to compaction of the present invention.In this law, with the uniform drying mixture of tamsulosin and inert excipient by compacting machine to obtain granule or banded batten (strands), then they are ground to form free-pouring powder, alternatively with other mixed with excipients and compacting in flakes.
Available suitable official method, as use the content uniformity of testing the tamsulosin tablet of institute's production batch according to the method for European Pharmacopoeia third edition Art.2.9.6.The appropriate methodology of measuring tamsulosin content in the tablet is high performance liquid chromatography (HPLC).A feature of the present invention is that the tablet a collection of of the present invention for preparing under the situation by liquid (tablet of dry process) does not show high content uniformity.Specifically, based on the target amount of tamsulosin active substance, the difference of the amount of tamsulosin active substance and target amount is 10% or littler in single batch, preferred 5% or littler, more preferably 2.5% or littler.Normally, in whole tabletting process, extract a few sample and test to confirm described content uniformity with regular intervals of time.
Can be used for the processing of the functional treatment of the medicable symptom benign prostatauxe of tamsulosin or hypertrophy (BPH) or other obstacle (the described obstacle of hereinafter referred) according to tamsulosin oral tablet of the present invention.
Therefore, the present invention further provides a kind of any or multiple method that treats and/or prevents in the described obstacle, it comprise need it the patient effectively and/or tamsulosin or its pharmaceutically acceptable acid-addition salts of preventive dose, particularly tamsulosin hydrochloride is used anhydrous method it is mixed with tablet.
The method that the present invention also provides the tamsulosin tablet composition of using the anhydrous process preparation and prepared tamsulosin tablet composition itself is used for the treatment of and/or prevents application in any or multiple medicine in the described obstacle in preparation.
Tablet composition of the present invention can also be applied in the medical applications with other combinations of substances.Form that can single combination preparation or realize described combination by the medicine that separately contains above-mentioned substance.
Further set forth the present invention by the following examples.
Embodiment 1
With progressively mixing and direct compression process has prepared three batches of monoblock type tablets:
A) tablet is formed
(％)
Tamsulosin hydrochloride 0.4mg 0.5
Lactis Anhydrous 26.4mg 33.0
Anhydrous dicalcium phosphate 26.4mg 33.0
Hydroxypropyl emthylcellulose (HPMC) 26.4mg 33.0
Magnesium stearate 0.4mg 0.5
Amount to 80mg 100
Difference between criticizing and criticizing only is the viscosity number of selected hydroxypropyl emthylcellulose:
Criticize A and contain METHOCEL K4M CR PREMIUM
Criticize B and contain METHOCEL K15M CR PREMIUM
Criticize C and contain METHOCEL K100M CR PREMIUM
B) operational approach
With ratio (10% the active substance) fusion (15 minutes) of tamsulosin hydrochloride and Lactis Anhydrous, grind (15 seconds) and then fusion (5 minutes) with 1: 9.Then this pre-admixture is mixed (10 minutes) with remaining part, dicalcium phosphate and the hydroxypropyl emthylcellulose of lactose, add magnesium stearate and mixing (5 minutes) at last, form the precommpression admixture.It is 97.2-100.4% in pre-admixture that this progressively hybrid system provides the homogeneity of tamsulosin, is 88.1-98.6% in the precommpression admixture).On Korsch EK0 tablet machine, carry out tabletting with standard speed and pressure.
C) feature of the tablet of Sheng Chaning
Batch Weight (mg) Hardness (N) Thickness (mm) Diameter (mm) Measure (%)
A 82.8 52 2.63 5.98 93.6
B 83.5 38 2.69 5.99 88.1
C 81.8 52 2.66 5.99 98.6
D) dissolution study
In 500ml phosphate buffer pH6.8, with the 50rpm rotating speed 6 tablets have been carried out dissolution test with the oar device.Be lower than 3% with the medicine of HPLC method mensuration release and the standard deviation of all batches.
Embodiment 2
Component
Raceme-tamsulosin hydrochloride 0.4mg
Lactis Anhydrous 25.6mg
Anhydrous dicalcium phosphate 25.6mg
Hydroxypropyl emthylcellulose (HPMC) 28.0mg
Magnesium stearate 0.4mg
Amount to 80mg
Production method
With tamsulosin and Lactis Anhydrous ratio (10% active substance) fusion (Turbula with 1: 9; 15 minutes), grind (IKA; 30 seconds) and then fusion (Turbula; 5 minutes).The yield of this method be 99.2% and tamsulosin be determined as 95.5%.Then this pre-admixture is mixed (Bohle LM40,5L container) with remaining part, dicalcium phosphate and the hydroxypropyl emthylcellulose of lactose.Estimate three progressively incorporation times (15,30 and 45 minutes), homogeneity in all cases all is excellent (tamsulosin is determined as 101.2%, 101.7% and 102.1%).At last, magnesium stearate is sieved, is added and mixes (Bohle LM40; 5 minutes), the total recovery and the tamsulosin of acquisition 99.7% are determined as 102.5%.In eccentric tablet machine Korsch EK0 or in rotary tablet machine Korsch XL100 with above-mentioned precommpression admixture tabletting (about 15000).The feature of described tablet shows below:
Tablet machine Weight (mg) c.v. (％) Hardness (N) S.D. (N) Thickness (mm) Diameter (mm) Measure (%)
Korsch EK0 79.8 1.00 75 5 2.58 6 --
Korsch XL100 80.9 1.50 85 7 2.55 6 103.2 *
Embodiment 3
With to embodiment 1 in the similar progressively hybrid plan that uses prepared following tablet.
Tamsulosin hydrochloride 0.4mg 0.4mg 0.4mg
Lactis Anhydrous 35.2mg 30.8mg 22.0mg
Anhydrous dicalcium phosphate 35.2mg 30.8mg 22.0mg
Hydroxypropyl emthylcellulose 8.8mg 17.6mg 35.2mg
Magnesium stearate 0.4mg 0.4mg 0.4mg
Amount to 80mg 80mg 80mg
Embodiment 4
Monoblock type sheet with the tight method preparation of dry-pressing
Compress with comprising, grind, the method for mixing and tabletting produced two batches of tablets.
Criticize 4a.: the monoblock type sheet that compresses, 6mm diameter.Contain 33.0%METHOCEL K15M P.
The monoblock type that crowd 4b. compresses can be lost sheet, the 9mm diameter.Contain 13.2%METHOCEL K15MP.
A) tablet is formed
Criticize 4a Criticize 4b
Tamsulosin hydrochloride 0.4mg 0.4mg
Lactose 65.6mg 215.6mg
Hydroxypropyl emthylcellulose (HPMC) 33.0mg 33.0mg
Magnesium stearate 1.0mg 1.0mg
Amount to 100mg 250mg
B) operational approach
With ratio (10% the active substance) fusion (15 minutes) of tamsulosin and Lactis Anhydrous, grind (15 seconds) and then fusion (5 minutes) with 1: 9.Then will this pre-admixture mix (10 minutes) with the magnesium stearate of the remaining part of lactose, hydroxypropyl emthylcellulose and 25%, in Chilsonator (Fitz-Patrick), compress and in Fitz-Mill (Fitz-Patrick), grind, the remaining part (75%) that adds magnesium stearate at last mixes (15 minutes) then.In Korsch EK0 tablet machine, carry out tabletting with standard speed and pressure.The feature of tablet is presented in the following table.
Batch Weight (mg) Hardness (N) Thickness (mm) Diameter (mm) Lubricating coefficient
4a 103.3 31 3.42 6 98.4
4b 251.6 42 3.71 9 100
Embodiment 5
Tamsulosin monoblock type slow releasing tablet by the direct compression process preparation
Charging:
Tamsulosin hydrochloride 4.0g
Eudragit RS PO 200.4g
Eudragit L 100 50.1mg
Microcrystalline Cellulose 736.1g
Magnesium stearate 10.1g
Will all the above-mentioned batchings except that magnesium stearate pack in the free-falling blender and it is stirred evenly by mixing 40 minutes.Add magnesium stearate and continue and mixed other 5 minutes.Prepared the heavy tablet of the 100mg that contains the 0.4mg tamsulosin hydrochloride by direct compression process by said mixture.
Embodiment 6
By the monoblock type coating slow releasing tablet that progressively mixes and direct compression process prepares
Charging:
Tamsulosin hydrochloride 18g
Eudragit RS PO 675g
Eudragit L100 225g
MCC 102 3527g
Magnesium stearate 45g
In the free-falling blender, tamsulosin was mixed 30 minutes with the 360g microcrystalline Cellulose, add the 1800g microcrystalline Cellulose and continue and mixed 30 minutes.The remaining part (1377g) and the above-mentioned two kinds of Eudragit that add microcrystalline Cellulose subsequently.In the free-falling blender, continue to mix 30 minutes.Add magnesium stearate and with other mixed with excipients 5 minutes.Prepare tablet with eccentric tablet machine.The tablet of the heavy 100mg of target, hardness 100N.2.5kg is with 5% coating materials coating.Used Bohle LC5 at 60 minutes in the clock time, the porous drum applies this 5% coating materials.
The coating materials prescription:
Eudragit L 30 D-55 416.5g
Triethyl citrate 12.5g
Pulvis Talci 37.5g
Water 450.0g
The present invention has now been described, it is evident that to one skilled in the art, can carry out easily or learn in reality and implement further change and modification in design described herein and the scheme, and not deviate from invention essence and the scope that limits as following claims by implementing the present invention.

Claims (34)

1. a medicinal tablet comprises 0.1 to 1.5% tamsulosin active substance and at least a pharmaceutically acceptable excipient, and this medicinal tablet is to obtain by the method for not using liquid.
2. according to the medicinal tablet of claim 1, wherein said tamsulosin active substance is tamsulosin free alkali, the pharmaceutically acceptable salt of tamsulosin or aforementioned any two or more mixture.
3. according to the medicinal tablet of claim 1 or 2, wherein said tamsulosin active substance is the form that is particle, and this particle has size distribution, and wherein at least 90% has 100 microns or littler particle size.
4. according to the medicinal tablet of claim 3, wherein said tamsulosin active substance has particle size distribution, and wherein at least 90% of said particle has 50 microns or littler size.
5. according to the medicinal tablet of claim 4, wherein said tamsulosin active substance has particle size distribution, and wherein at least 90% of said particle has 20 microns or littler size.
6. according to the medicinal tablet of claim 4, wherein said tamsulosin active substance has particle size distribution, and wherein at least 90% of said particle has 10 microns or littler size.
7. according to the medicinal tablet of claim 1 or 2, wherein contain said tamsulosin active substance with 0.2 to 1.0% amount.
8. according to the medicinal tablet of claim 7, wherein contain said tamsulosin active substance with 0.2 to 0.8% amount.
9. according to the medicinal tablet of claim 7, wherein contain said tamsulosin active substance with 0.3 to 0.6% amount.
10. according to the medicinal tablet of claim 1 or 2, wherein contain said tamsulosin active substance with the amount that is equivalent to 0.3mg to 1.2mg tamsulosin free alkali.
11. according to the medicinal tablet of claim 1 or 2, to be tamsulosin hydrochloride and this tablet contain said material with the amount of 0.4mg+/-0.04 to wherein said tamsulosin active substance.
12. according to the medicinal tablet of claim 1 or 2, it comprises at least a pharmaceutically acceptable excipient, this excipient is selected from the group of being made up of polymer, carbohydrate and compressible diluent.
13. according to the medicinal tablet of claim 12, it comprises a kind of polymer, this polymer is selected from the group of being made up of acrylate polymer class and cellulose family.
14. according to the medicinal tablet of claim 12, wherein said polymer is selected from HPMC and microcrystalline Cellulose.
15. according to the medicinal tablet of claim 12, it comprises lactose.
16. according to the medicinal tablet of claim 12, it comprises calcium phosphate.
17. according to the medicinal tablet of claim 12, it comprises lactose, HPMC, calcium phosphate and magnesium stearate.
18. according to the medicinal tablet of claim 1 or 2, it is the monoblock type tablet.
19. according to the medicinal tablet of claim 18, it is a slow release monoblock type tablet.
20. according to the medicinal tablet of claim 1 or 2, it also comprises outer coating.
21. according to the medicinal tablet of claim 1 or 2, wherein said tablet is a prolongation release tablet once a day.
22. a collection of medicinal tablet, the sheet that comprises a large amount of dry processes, this sheet contains tamsulosin active substance and at least a pharmaceutically acceptable excipient between 0.1 and 1.5%, wherein the difference of the amount of tamsulosin active substance and described target amount be not more than+/-10%.
23. according to a collection of medicinal tablet of claim 22, the difference of wherein said tamsulosin active substance is not more than+and/-5%.
24. according to a collection of medicinal tablet of claim 23, the difference of wherein said tamsulosin active substance is not more than+and/-2.5%.
25. tamsulosin is used for the treatment of or improves application in the unit dosage forms of benign prostatic hyperplasia situation in preparation, wherein said unit dosage forms comprise effective dose one or more pieces according to each tablet of claim 1～21.
26. according to the application of claim 25, wherein said unit dosage forms comprise two or more multi-disc place the said tablet of capsule.
27. prepare the method for tamsulosin tablet, it is not included in and forms tablet under the situation by liquid, wherein said tablet contains 0.1 to 1.5% tamsulosin active substance and at least a pharmaceutically acceptable excipient.
28. according to the method for claim 27, it comprises:
With tamsulosin active substance and a kind of pharmaceutically acceptable excipient fusion and form first admixture;
Additionally said first admixture and one or more other excipient are gone on foot or the multistep fusion with one, form the precommpression admixture; And
With said precommpression admixture compacting in flakes.
29. according to the method for claim 27 or 28, wherein said first admixture stands to grind before itself and other excipient fusion.
30. according to the method for claim 27 or 28, wherein said other fusion also comprises: form the compact of fusion material after with at least a other excipient and the said first admixture fusion and grind said compact and form second admixture.
31. according to the method for claim 30, wherein said second admixture is said precommpression admixture.
32. according to the method for claim 30, wherein also with said second admixture and other excipient fusion and form said precommpression admixture.
33. according to the method for claim 27 or 28, wherein said tamsulosin active substance is the form that is particle, this particle has size distribution, and wherein at least 90% has 100 microns or littler particle size.
34. the tamsulosin tablet that obtains by each method of claim 28～33.
CNB028217357A 2001-11-07 2002-11-01 Tamsulosin tablets Expired - Fee Related CN1298317C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33105501P 2001-11-07 2001-11-07
US60/331,055 2001-11-07

Publications (2)

Publication Number Publication Date
CN1652760A CN1652760A (en) 2005-08-10
CN1298317C true CN1298317C (en) 2007-02-07

Family

ID=23292437

Family Applications (3)

Application Number Title Priority Date Filing Date
CNB028217357A Expired - Fee Related CN1298317C (en) 2001-11-07 2002-11-01 Tamsulosin tablets
CNA028229223A Pending CN1589139A (en) 2001-11-07 2002-11-06 Modified release tamsulosin tablets
CN2011102907062A Pending CN102327250A (en) 2001-11-07 2002-11-06 Adjustment release tamsulosin tablet

Family Applications After (2)

Application Number Title Priority Date Filing Date
CNA028229223A Pending CN1589139A (en) 2001-11-07 2002-11-06 Modified release tamsulosin tablets
CN2011102907062A Pending CN102327250A (en) 2001-11-07 2002-11-06 Adjustment release tamsulosin tablet

Country Status (21)

Country Link
US (2) US20030147950A1 (en)
EP (3) EP1443917B1 (en)
JP (3) JP2005512997A (en)
CN (3) CN1298317C (en)
AT (3) ATE321544T1 (en)
AU (1) AU2002301845B2 (en)
CA (2) CA2465110A1 (en)
CZ (3) CZ16809U1 (en)
DE (4) DE60210315T2 (en)
DK (3) DK1443917T3 (en)
ES (2) ES2256544T3 (en)
HU (2) HUP0401978A3 (en)
IL (4) IL161491A0 (en)
NL (2) NL1021822C2 (en)
NO (2) NO20042374L (en)
NZ (2) NZ532589A (en)
PT (2) PT1443917E (en)
RU (2) RU2311903C2 (en)
SI (2) SI1443917T1 (en)
WO (2) WO2003039530A1 (en)
ZA (2) ZA200403281B (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1443917T1 (en) * 2001-11-07 2006-06-30 Synthon Bv Tamsulosin tablets
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
IN192381B (en) * 2002-12-20 2004-04-10 Ranbaxy Lab
US20040253309A1 (en) * 2003-01-27 2004-12-16 Yamanouchi Pharmaceutical Co., Ltd. Enteric sustained-release fine particles of tamsulosin and its salt and manufacturing method thereof
EA200600066A1 (en) * 2003-07-01 2006-06-30 Крка, Товарна Здравил, Д.Д. Ново Место Tamsulozine-containing core coated with polyvinylpyrrolidone or polyvinyl acetate
KR100762846B1 (en) * 2003-09-29 2007-10-04 씨제이 주식회사 Sustained-release formulations
JP2007507491A (en) * 2003-09-29 2007-03-29 シージェー コーポレーション Sustained release formulation
JP2005104914A (en) * 2003-09-30 2005-04-21 Kyowa Yakuhin Kogyo Kk Basic agent-containing pharmaceutical preparation
US8128958B2 (en) * 2003-11-10 2012-03-06 Astellas Pharma Inc. Sustained release pharmaceutical composition
JP2005162736A (en) * 2003-11-10 2005-06-23 Astellas Pharma Inc Sustained release medicinal composition
US8197846B2 (en) * 2003-11-10 2012-06-12 Astellas Pharma Inc. Sustained release pharmaceutical composition
JP2005162737A (en) * 2003-11-10 2005-06-23 Astellas Pharma Inc Sustained release medicinal composition
WO2005053659A1 (en) * 2003-12-03 2005-06-16 Natco Pharma Limited An improved pharmaceutical formulation containing tamsulosin salt and a process for its preparation
SI21702A (en) * 2004-01-29 2005-08-31 Lek Farmacevtska Druzba Dd Preparation of amorphous form of tamsulosin
JP4603803B2 (en) * 2004-01-30 2010-12-22 大洋薬品工業株式会社 Controlled release pharmaceutical composition and formulation using the same
PL204079B1 (en) * 2004-08-12 2009-12-31 Inst Farmaceutyczny Oral solid tamsulozine hydrochloride preparation with prolonged release and method for its manufacture
WO2006055659A2 (en) * 2004-11-15 2006-05-26 Smithkline Beecham Corporation Fixed dose combination op dutasteride and tamsulosin
US20060159753A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
JP2008525313A (en) 2004-12-27 2008-07-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 Anti-dementia drug stabilization method
US20060160852A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Composition containing anti-dementia drug
KR100678421B1 (en) * 2005-02-11 2007-02-02 주식회사 씨티씨바이오 Controlled-release formulation containing tamsulosin hydrochloride
KR101213345B1 (en) * 2005-04-28 2012-12-17 에자이 알앤드디 매니지먼트 가부시키가이샤 Composition containing anti-dementia drug
CN1895241B (en) * 2005-07-12 2010-05-12 可隆制药株式会社 Composition of long-acting oral pills of Yansuan Tanshuluoxin and its production method
WO2007017253A1 (en) * 2005-08-10 2007-02-15 Add Advanced Drug Delivery Technologies Ltd. Oral preparation with controlled release of a benzenesulphonamide
KR20070021806A (en) * 2005-08-19 2007-02-23 (주)아모레퍼시픽 Sustained-release pellet formulation of ?1-receptor antagonist and process for the preparation thereof
KR20070044911A (en) * 2005-10-26 2007-05-02 주식회사 씨티씨바이오 Controlled-release formulation containing tamsulosin hydrochloride
WO2007131804A1 (en) * 2006-05-17 2007-11-22 Synthon B.V. Tablet composition with a prolonged release of tamsulosin
US20090004284A1 (en) * 2007-06-26 2009-01-01 Watson Pharmaceuticals, Inc. Controlled release tamsulosin hydrochloride formulation
EP2042169A1 (en) * 2007-09-26 2009-04-01 LEK Pharmaceuticals D.D. Controlled release tamsulosin hydrochloride tablets and a process of making them
TWI478712B (en) 2008-09-30 2015-04-01 Astellas Pharma Inc Pharmaceutical composition for modified release
US8465770B2 (en) * 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
JP5849947B2 (en) 2010-03-29 2016-02-03 アステラス製薬株式会社 Controlled release pharmaceutical composition
EP2564837B1 (en) 2010-04-30 2019-01-30 Takeda Pharmaceutical Company Limited Enteric tablet
US20140335174A1 (en) * 2011-05-25 2014-11-13 Taiho Pharmaceutical Co., Ltd. Dry-coated tablet containing tegafur, gimeracil and oteracil potassium
CN102579392A (en) * 2012-03-30 2012-07-18 重庆科瑞制药(集团)有限公司 Slow-release preparation containing tamsulosin hydrochloride and preparation method thereof
US10543174B2 (en) 2016-04-25 2020-01-28 Synthon B.V. Modified release tablet composition comprising mirabegron
US10478399B2 (en) 2017-10-12 2019-11-19 Synthon B.V. Modified release tablet composition comprising mirabegron
EP3292864A1 (en) 2017-10-12 2018-03-14 Synthon B.V. Modified release tablet composition comprising mirabegron
CA3078568A1 (en) 2017-10-12 2019-04-18 Synthon B.V. Modified release tablet composition comprising mirabegron
WO2019076966A1 (en) 2017-10-17 2019-04-25 Synthon B.V. Tablets comprising tamsulosin and solifenacin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772475A (en) * 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
WO1998037872A2 (en) * 1997-02-28 1998-09-03 Cygnus, Inc. Transdermal drug delivery system for the administration of tamsulosin, and related compositions and methods of use
WO2001074390A2 (en) * 2000-04-04 2001-10-11 Pfizer Limited The use of a calcium channel blocker for treating renal disorders

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56110665A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
US5391825A (en) * 1980-02-08 1995-02-21 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl substituted phenethylamine intermediates
DE3681348D1 (en) * 1985-06-11 1991-10-17 Teijin Ltd ORAL DRUG PREPARATION WITH RETARDIVE EFFECT.
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
IE60311B1 (en) * 1987-09-24 1994-06-29 American Home Prod Sustained release etodolac
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
CA2147866A1 (en) * 1992-11-04 1994-05-11 Nancy M. Gray Methods and compositions of (+) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis
IL109460A (en) * 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
CA2166812A1 (en) * 1993-07-14 1995-01-26 Masaharu Asano Agent for treating urinary outlet obstruction associated with benign prostatic hyperplasia
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5503843A (en) * 1994-04-22 1996-04-02 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
JPH09323926A (en) * 1996-03-15 1997-12-16 Nikken Chem Co Ltd Sustained release tablet of sodium valproate
JP2001507359A (en) * 1997-01-03 2001-06-05 エラン コーポレーション ピーエルシー Sustained release cisapride mini tablet formulation
JP4221068B2 (en) * 1997-12-17 2009-02-12 興和創薬株式会社 Theophylline sustained release tablet and method for producing the same
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
TW536402B (en) * 1998-06-26 2003-06-11 Yamanouchi Pharma Co Ltd Pharmaceutical composition for the therapy of voiding dysfunction
JP2000080032A (en) * 1998-06-26 2000-03-21 Yamanouchi Pharmaceut Co Ltd Remedy for excretion disorder
JP2000128774A (en) * 1998-10-26 2000-05-09 Tanabe Seiyaku Co Ltd Production of globular, fine grain including medicine
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CA2371940C (en) * 1999-03-31 2008-07-15 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
EP1178780B1 (en) * 1999-05-20 2007-07-18 ELAN CORPORATION, Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
JP3154710B1 (en) * 1999-08-09 2001-04-09 山之内製薬株式会社 Lower urinary tract disorders
CA2370501C (en) * 1999-08-09 2008-09-16 Yamanouchi Pharmaceutical Co., Ltd. Pharmaceutical composition for the therapy of lower urinary tract symptoms
GB9924020D0 (en) * 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the manufacture of a medicament for the treatment of benign prostatic hyperplasia
US6368628B1 (en) * 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
DE10109763A1 (en) * 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmaceutical salts
RU2245136C2 (en) * 2001-07-27 2005-01-27 Яманоути Фармасьютикал Ко., ЛТД Composition containing fine dispersed long releasing particles for quick-disposable in buccal cavern tablets
SI1443917T1 (en) * 2001-11-07 2006-06-30 Synthon Bv Tamsulosin tablets

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772475A (en) * 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
WO1998037872A2 (en) * 1997-02-28 1998-09-03 Cygnus, Inc. Transdermal drug delivery system for the administration of tamsulosin, and related compositions and methods of use
WO2001074390A2 (en) * 2000-04-04 2001-10-11 Pfizer Limited The use of a calcium channel blocker for treating renal disorders

Also Published As

Publication number Publication date
HUP0401978A3 (en) 2008-07-28
RU2004117080A (en) 2005-04-10
WO2003039530A1 (en) 2003-05-15
ES2287333T3 (en) 2007-12-16
AU2002301845B2 (en) 2008-06-05
IL161525A (en) 2012-12-31
RU2311903C2 (en) 2007-12-10
ATE369128T2 (en) 2007-08-15
DE20221486U1 (en) 2006-02-02
US20030147955A1 (en) 2003-08-07
ES2256544T3 (en) 2006-07-16
HU230830B1 (en) 2018-07-30
EP1595538A3 (en) 2006-02-22
RU2004117081A (en) 2005-03-20
EP1443917A1 (en) 2004-08-11
NL1021822A1 (en) 2003-05-08
SI1441713T2 (en) 2019-03-29
AT9978U1 (en) 2008-07-15
DK200500297U3 (en) 2006-03-10
HUP0401978A2 (en) 2005-01-28
ES2287333T5 (en) 2019-04-29
PT1441713E (en) 2007-08-28
ATE321544T1 (en) 2006-04-15
CA2465110A1 (en) 2003-05-15
US20030147950A1 (en) 2003-08-07
NZ532589A (en) 2005-02-25
DK1443917T3 (en) 2006-07-17
NO20042374L (en) 2004-08-09
EP1441713A1 (en) 2004-08-04
HUP0402004A3 (en) 2008-08-28
DE60210315D1 (en) 2006-05-18
DE20220415U1 (en) 2003-10-09
SI1441713T1 (en) 2007-10-31
HUP0402004A2 (en) 2005-01-28
IL161491A (en) 2009-07-20
DE60221691T3 (en) 2019-04-04
IL161525A0 (en) 2004-09-27
NO340960B1 (en) 2017-07-31
DE60221691T2 (en) 2008-04-30
ZA200403281B (en) 2005-12-13
ZA200403430B (en) 2006-02-22
PT1443917E (en) 2006-06-30
CZ16809U1 (en) 2006-08-28
DE60210315T2 (en) 2006-11-02
IL161491A0 (en) 2004-09-27
JP2011051995A (en) 2011-03-17
DE60221691D1 (en) 2007-09-20
CA2464689A1 (en) 2003-05-15
NL1021822C2 (en) 2003-07-15
CZ16814U1 (en) 2006-08-28
NL1021857C2 (en) 2004-01-09
JP2005511591A (en) 2005-04-28
DK1441713T4 (en) 2019-02-18
NO20042375L (en) 2004-08-09
CN102327250A (en) 2012-01-25
NL1021857A1 (en) 2003-05-08
JP2005512997A (en) 2005-05-12
CN1589139A (en) 2005-03-02
EP1595538A2 (en) 2005-11-16
CA2464689C (en) 2011-02-01
EP1441713B1 (en) 2007-08-08
DK1441713T3 (en) 2007-12-17
EP1443917B1 (en) 2006-03-29
CN1652760A (en) 2005-08-10
WO2003039531A1 (en) 2003-05-15
SI1443917T1 (en) 2006-06-30
CZ16813U1 (en) 2006-08-28
JP5536610B2 (en) 2014-07-02
NZ532592A (en) 2005-02-25
EP1441713B2 (en) 2018-11-14
RU2335280C2 (en) 2008-10-10

Similar Documents

Publication Publication Date Title
CN1298317C (en) Tamsulosin tablets
CN1155368C (en) Powdery composition for nasal administration
CN1303998C (en) Pharmaceutical formulations containing darifenacin
CN1220485C (en) Method for making granules with masked taste and instant release of active particle
CN1195498C (en) Directly compressed solid dosage particles
JP2017075192A (en) Coated tablet formulation
CN1691965A (en) Pharmaceutical composition for controlled release and manufacturing method thereof
CN1886119A (en) Pantoprazole multiparticulate formulations
CN1946382A (en) Rapid dissolution formulation of a calcium receptor-active compound
FR2847166A1 (en) DOSAGE FORM COMPRISING CLOSED TAMSULOSIN PAGS, METHOD FOR PREPARING THE SAME, AND USE THEREOF
CN1607947A (en) Delayed release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
CN1296412A (en) Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
CN1688291A (en) Immediate release dosage forms containing solid drug dispersions
CN1282239A (en) Spheroids, preparation method and pharmaceutical compositions
CN1315853A (en) Bioenhanced formulations comprising eprosartan in oral dosage form
CN101056658A (en) Oral preparation having improved bioavailability
CN1747723A (en) Composition comprising a mixture of active principles, and method of preparation
CN1469737A (en) Medicinal compositions quickly disintegrating in the oral cavity and process for producing the same
CN1309375C (en) Granulating process of medicinal material and supplementary material for dispensing directly
CN1330546A (en) Compositions comprising cefuroxime axetil
CN1095665C (en) Modified-release metronidazole compositions and methods for making and using same
CN1285738A (en) Novel oral dosage form for carvedilol
CN1455691A (en) Pharmaceutical compositions
CN1954803A (en) Spray-dried granules containing pranlukast and processes for the preparation thereof
CN100506222C (en) Preparing method for controlled released type tablet tamsulosin hcl and the tablet thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070207

Termination date: 20091201